Research programme: neuroprotectants - Trophos

Drug Profile

Research programme: neuroprotectants - Trophos

Alternative Names: Cholesterol-oxime compounds - Roche; TRO-11592; TRO-17416; TRO-20021; TRO-51644; TRO-6391

Latest Information Update: 01 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Trophos
  • Developer Roche
  • Class Cholestenones; Oximes; Small molecules
  • Mechanism of Action Mitochondrial permeability transition pore modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Huntington's disease; Multiple sclerosis; Neurological disorders; Neuropathic pain; Pain; Parkinson's disease; Reperfusion injury; Spinal muscular atrophy

Most Recent Events

  • 28 Sep 2010 A lead compound from this programme, TRO 40303, has entered clinical development
  • 20 Jul 2010 Actelion agrees to an exclusive option to acquire Trophos
  • 18 Feb 2009 Trophos awarded funding worth up to €7 million for two projects, as part of its research programme to develop cholesterol-oxime compounds for various Neurological disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top